

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
Date of first issue: 11/07/2014

SECTION 1. IDENTIFICATION

Product name : Sitagliptin / Metformin Extended Release Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H302 Harmful if swallowed.

Precautionary Statements : **Prevention:**
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
 Date of first issue: 11/07/2014

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
 Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
metformin hydrochloride	1115-70-4	>= 50 - < 70
Cellulose	9004-34-6	>= 10 - < 20
Sitagliptin	654671-77-9	>= 5 - < 10
Kaolin	1332-58-7	>= 1 - < 5
Titanium dioxide	13463-67-7	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
 Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
 Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
 Get medical attention.
 Rinse mouth thoroughly with water.
 Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Harmful if swallowed.
 Contact with dust can cause mechanical irritation or drying of the skin.
 Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire : Avoid generating dust; fine dust dispersed in air in sufficient

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

-
- | | |
|--|---|
| fighting | concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides
Metal oxides
Nitrogen oxides (NOx)
Silicon oxides |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment for fire-fighters | : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- | | |
|---|--|
| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

SECTION 7. HANDLING AND STORAGE

- | | |
|-------------------------|--|
| Technical measures | : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : Use only with adequate ventilation. |
| Advice on safe handling | : Do not breathe dust.
Do not swallow. |

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
 Date of first issue: 11/07/2014

Avoid contact with eyes.
 Avoid prolonged or repeated contact with skin.
 Wash skin thoroughly after handling.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Do not eat, drink or smoke when using this product.
 Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
metformin hydrochloride	1115-70-4	TWA	1 mg/m ³ (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Sitagliptin	654671-77-9	TWA	0.5 mg/m ³ (OEB 2)	Internal
Kaolin	1332-58-7	TWA (Respirable particulate matter)	2 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Titanium dioxide	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (Respirable particulate matter)	2.5 mg/m ³ (Titanium dioxide)	ACGIH

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
 Date of first issue: 11/07/2014

		ter)		
		TWA (Respirable particulate matter)	0.2 mg/m ³ (Titanium dioxide)	ACGIH

This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Titanium dioxide

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material

: Chemical-resistant gloves

Eye protection

: Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
Hygiene measures

: Work uniform or laboratory coat.
 : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

SAFETY DATA SHEET



Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
Date of first issue: 11/07/2014

Color : blue green

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
Date of first issue: 11/07/2014

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,588 mg/kg
Method: Calculation method

Components:

metformin hydrochloride:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg
LD50 (Mouse): 1,450 - 3,500 mg/kg
LD50 (Monkey): 463 mg/kg
LD50 (Rabbit): 350 mg/kg
LD50 (Guinea pig): 500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
Date of first issue: 11/07/2014

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Kaolin:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 2.07 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**metformin hydrochloride:**

Species : Rabbit
Result : Mild skin irritation

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Kaolin:

Species : Rabbit
Method : OECD Test Guideline 404

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
Date of first issue: 11/07/2014

Result : No skin irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Rabbit
Result : Mild eye irritation

Sitagliptin:

Species : Rabbit
Result : Irritating to eyes.
Method : Draize Test

Kaolin:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Sitagliptin:

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse

**Sitagliptin / Metformin Extended Release For-
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**metformin hydrochloride:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro test
Test system: mouse lymphoma cells
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-
thesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Application Route: Oral
Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

metformin hydrochloride:

Species : Mouse
Exposure time : 91 weeks
Dose : 1500 mg/kg body weight
Result : negative

Species : Rat, male
Application Route : Oral
Exposure time : 104 weeks
Dose : 900 mg/kg body weight
Result : negative

Species : Rat, female
Application Route : Oral
Exposure time : 104 weeks
LOAEL : 900 mg/kg body weight
Result : negative
Target Organs : Uterus (including cervix)
Remarks : The mechanism or mode of action may not be relevant in humans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Sitagliptin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : oral (drinking water)

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Exposure time : 2 Years
 Result : positive
 Target Organs : Liver
 Remarks : Significant toxicity observed in testing

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

Titanium dioxide:

Species : Rat
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 Years
 Method : OECD Test Guideline 453
 Result : positive
 Remarks : The mechanism or mode of action may not be relevant in humans.
 This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

IARC Group 2B: Possibly carcinogenic to humans
 Titanium dioxide 13463-67-7

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

metformin hydrochloride:

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 600 mg/kg body weight
 Result: No effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 600 mg/kg body weight
 Result: No teratogenic effects.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-fetal toxicity.: NOAEL: 140 mg/kg body weight

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL Parent: 1,000 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Teratogenicity: LOAEL: 250 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development
Species: Rabbit
Teratogenicity: NOAEL: 125 mg/kg body weight
Result: No teratogenic effects.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

metformin hydrochloride:

Species : Rat
NOAEL : 125 mg/kg
Application Route : Oral
Exposure time : 1 year
Remarks : No significant adverse effects were reported

Species : Rabbit
NOAEL : 100 mg/kg
Application Route : Oral

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Exposure time : 1 Year
 Remarks : No significant adverse effects were reported

Species : Dog
 NOAEL : 50 mg/kg
 Application Route : Subcutaneous
 Exposure time : 2 year
 Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat
 NOAEL : $\geq 9,000$ mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Sitagliptin:

Species : Mouse
 NOAEL : 500 mg/kg
 LOAEL : 1,000 mg/kg
 Application Route : Oral
 Exposure time : > 2 y
 Target Organs : Kidney

Species : Rat
 NOAEL : 500 mg/kg
 LOAEL : 1,000 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
 NOAEL : 10 mg/kg
 LOAEL : 50 mg/kg
 Application Route : Oral
 Exposure time : 53 Weeks
 Target Organs : Central nervous system
 Symptoms : Loss of balance
 Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Dog
 NOAEL : 2 mg/kg
 LOAEL : 10 mg/kg
 Application Route : Oral
 Exposure time : 27 Weeks
 Target Organs : Skeletal muscle, Central nervous system
 Symptoms : Loss of balance
 Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey
 NOAEL : 100 mg/kg

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Application Route : Oral
 Exposure time : 14 Weeks
 Remarks : No significant adverse effects were reported

Titanium dioxide:

Species : Rat
 NOAEL : 24,000 mg/kg
 Application Route : Ingestion
 Exposure time : 28 Days

Species : Rat
 NOAEL : 10 mg/m³
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

metformin hydrochloride:

Skin contact : Remarks: May irritate skin.
 Eye contact : Remarks: May irritate eyes.
 Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal discomfort, flatulence, asthenia, Fatigue, Headache

Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis, Headache
 Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhea

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

metformin hydrochloride:

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l
 Exposure time: 33 d

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 40 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 60 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 150 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

Kaolin:

Toxicity to fish (Chronic toxicity) : NOELR (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 30 d

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

metformin hydrochloride:

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 2 hrs

Cellulose:

Biodegradability : Result: Readily biodegradable.

Sitagliptin:

Biodegradability : Result: not rapidly degradable
Biodegradation: 39.7 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)
Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

metformin hydrochloride:

Partition coefficient: n-octanol/water : log Pow: -2

Sitagliptin:

Partition coefficient: n-octanol/water : log Pow: -0.03

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
Date of first issue: 11/07/2014

Mobility in soil

Components:

metformin hydrochloride:

Distribution among environmental compartments : log Koc: 4.3
Method: OECD Test Guideline 106

Sitagliptin:

Distribution among environmental compartments : log Koc: 4.37

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Acute toxicity (any route of exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

metformin hydrochloride	1115-70-4
Hydroxypropyl methylcellulose	9004-65-3
Cellulose	9004-34-6
Sitagliptin	654671-77-9
Polyvinyl pyrrolidone	9003-39-8
Kaolin	1332-58-7

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous Substances

Polyvinyl pyrrolidone	9003-39-8
-----------------------	-----------

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Kaolin	1332-58-7

The ingredients of this product are reported in the following inventories:


AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

Sitagliptin / Metformin Extended Release Formulation

Version 10.2 Revision Date: 10/01/2022 SDS Number: 29118-00022 Date of last issue: 04/09/2022
 Date of first issue: 11/07/2014

NFPA 704:**HMIS® IV:**

HEALTH	/	1
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); EC_x - Concentration associated with x% response; EHS - Extremely Hazardous Substance; EL_x - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErC_x - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC₅₀ - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC₅₀ - Lethal Concentration to 50 % of a test population; LD₅₀ - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

Sitagliptin / Metformin Extended Release Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/09/2022
10.2	10/01/2022	29118-00022	Date of first issue: 11/07/2014

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/01/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8